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abstract
4-Methylimidazole (4MeI) is a tremorogenic and convulsive agent of concern both in human and veterinary 
  toxicology. The in vitro effects of 4MeI (5 µM–20 mM) on cerebral glutamate decarboxylase (GAD) activity and 
(in concentrations up to 50 mM) on binding of [3H]GABA to cerebral GABA receptors were tested in brain tissue 
from B6D2 mice. The effects of 1-methylimidazole (1MeI), 2-methylimidazole (2MeI), 4-methylhydroxy-imidazole 
(4MeOHI), imidazole-4-acetic acid (4AcI) (all in concentrations of 5–20 mM) and imidazole (20 mM) on GAD activ-
ity were also tested. In addition, the effect of a lethal dose of 4MeI (250 mg/kg ip) to B6D2 mice in vivo on the 
postmortem concentrations of γ-aminobutyric acid (GABA) and glutamate in their brains were measured. In all 
experiments, student’s t-test was used for statistical comparison. 4MeI in concentrations of 2 mM and above did 
inhibit GAD activity significantly in vitro, but glutamate and GABA concentrations in mouse brains after lethal 
4MeI poisoning were not significantly different from control values. The effect of 2MeI on GAD activity was 
stronger than the effect of 4MeI. Binding of [3H]GABA to cerebral GABA receptors in vitro was significantly inhib-
ited only at 4MeI concentrations of 5 mM and above. The results indicate that neither inhibition of GABA synthe-
sis nor competitive inhibition of the binding of GABA to its receptors are likely mechanisms for the excitation and 
convulsions seen in 4MeI poisoning in animals.
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Introduction
The  toxicity  of  4-methylimidazole  (4MeI)  is  a  matter  of 
concern both in human and veterinary toxicology (Morgan 
2004; Chan et  al. 2008). The substance was first identified as 
a tremorogenic and convulsive agent by Nishie et al. (1969), 
after the observation of violent signs of CNS toxicity in cattle 
fed ammoniated molasses (Wiggins 1956). 4MeI induces the 
same signs of toxicity whether it is given orally or parenter-
ally. Nishie et al. (1969) determined the po LD50 to 370 mg/kg,   
and the ip LD50 to 165 mg/kg.
The  mechanism  behind  the  excitatory  and  convulsive 
effects of 4MeI is not known. The effects can be counteracted 
by chlordiazepoxide and by sodium phenobarbital (Nishie 
et al. 1969). Both these drugs are considered to exert their 
main effect via GABAA receptors in the brain (Charney et al. 
2006). Similarity of the clinical signs induced by 4MeI and 
by  known  inhibitors  of  GABA  synthesis  such  as  mercap-
topropionic  acid  and  mercaptobutyric  acid  (Lamar  1970; 
Karlsson et al. 1974) does also hint at the GABA system as a 
possible target for 4MeI toxicity. In experimental 4MeI poi-
soning, sudden appearance of dramatic convulsions after 
a dose-dependent latent period is characteristic (Sivertsen 
and Müller 1999). This picture could be consistent with a 
build-up or depletion mechanism in the mouse brain, such 
as the depletion of cerebral GABA levels induced by inhibi-
tors of cerebral GAD activity (Karlsson et al. 1974).4-methylimidazole and GABA in mice    215
On this background, the present study was designed to 
clarify if 4MeI has sufficient effect on cerebral GABA syn-
thesis or on specific GABA receptor binding to explain the 
excitatory and convulsive effects of the substance. The study 
was divided into three parts: an investigation of the effects of 
4MeI on mouse brain glutamate decarboxylase (GAD) activ-
ity in vitro, an investigation of the effects of acute 4MeI poi-
soning on the immediate post-mortem GABA and glutamate 
concentrations in the mouse brain, and an investigation of 
the effects of 4MeI on specific [3H]GABA receptor binding in 
mouse brain synaptosomal membranes in vitro.
Materials and methods
Animals
All animals were B6D2 mice (Norwegian Institute of Public 
Health, Oslo). They were caged in groups of 10 with free 
access to food and tap water, with a 12-hour light/day cycle, 
a relative humidity of 50%, and a room temperature of 25°C. 
Ca 60 animals were used altogether. The experimental work 
was conducted at and approved by the Norwegian Defence 
Research Establishment at Kjeller, Norway. The experimen-
tal animals were handled in accordance with institutional 
and national guidelines for animal research.
Effect of 4MeI on GAD activity
GAD can be obtained in a soluble form after hypotonic shock 
of nerve terminals (Fonnum 1968). B6D2 mice were eutha-
nized by cervical dislocation. The brain was taken out and 
homogenized in 20 volumes of 0.32 M sucrose. The homoge-
nate was centrifuged at 700 xg for 10 minutes. The pellet was 
discarded and the supernatant centrifuged at 13 000 xg for 
30 minutes. The pellet from this centrifugation was shocked 
with cold, distilled water, re-homogenized and centrifuged at 
20 000 xg for 30 minutes. The supernatant, hereafter referred 
to as brain enzyme extract, was used for the GAD assays.
GAD activity was assayed by a modified version of the 
radiochemical  method  described  by  Albers  and  Brady 
(1959) and Fonnum et al. (1970). The brain enzyme extract 
(2 µl) was mixed with varying concentrations of 4MeI and 
with a prepared incubation solution, to a total volume of 4 µl 
in each test tube. The final mixture contained 11 µCi/ml Na 
L-[1-14C]-glutamate,  9.2 mM  Na  L-glutamate,  9.3 µM  pyri-
doxal phosphate, 0.84 mM dithiotreitol, 18.9 mM NaH2PO4 
buffer, and 0.24% Triton X-100. The final pH was 6.5. The 
final 4MeI concentrations used were 5 µM, 50 µM, 100 µM, 
500 µM, 1 mM, 2 mM, 5 mM, and 10 mM.
The assay was run four times with each 4MeI concentra-
tion, with controls (without 4MeI) and with blanks (without 
brain  enzyme  extract).  Through  previous  experiments  it 
was confirmed that the activity recorded was linear with the 
amount of GAD enzyme (Fonnum et al. 1970). The whole 
experiment was repeated three times, and the results cal-
culated as activity in percent of controls. Thereafter, GAD 
activity assays were repeated with the following variations 
in  experimental  conditions:  with  4MeI  concentration 
fixed  at  5 mM,  the  assays  were  run  with  Na  L-glutamate 
concentrations of 9.2 mM, 2.3 mM, and 575 µM. With 4MeI 
concentration at 5 mM and Na L-glutamate at 2.3 mM, the 
assays were also run with pyridoxal phosphate concentra-
tions of 9.3 µM, 4.7 µM, 2.3 µM, 0.9 µM, and 0 µM. The assay 
was run at least six times for each set of concentrations.
With Na-L glutamate concentration at 2.3 mM and pyridoxal 
phosphate at 9.3 µM, a comparative study of the effects of the 
following substituted imidazoles were carried out, in concen-
trations from 5–20 mM (minimum of six repeats per substance 
and concentration): 4MeI, 1-methyl imidazole (1MeI), 2-methyl 
imidazole (2MeI), 4-hydroxymethyl imidazole (4MeOHI), and 
imidazole-4-acetic acid (4AcI). In addition, the effect of 20 mM 
unsubstituted imidazole was tested.
Concentrations of GABA and glutamate in mouse brain 
after lethal poisoning with 4MeI
Ten B6D2 mice, weighing 31–39 g, were used. Mouse no. 1   
was given 250 mg 4MeI/kg body weight ip, and mouse no. 2 
was given an equal volume of 0.9% NaCl solution ip imme-
diately  afterwards,  to  serve  as  control.  When  mouse  no. 
1  developed  violent  convulsions  and  died  (Sivertsen  and 
Müller 1999), mouse no. 2 was immediately euthanized by 
cervical dislocation. The same procedure was repeated with 
mice no. 3 and 4, no. 5 and 6, etc.
The heads of the dead and euthanized mice were imme-
diately cooled in liquid N2, and the brains were dissected out 
on ice. Each brain was homogenized in 6 ml 2.5% trichlo-
roacetic  acid,  with  0.5 mM  -aminoadipic  acid  added  as 
internal standard. The homogenate was centrifuged for 10 
minutes at 15,000 rpm. The supernatant was extracted three 
times  with  ethyl  ether  to  remove  non-polar  substances. 
Concentrations of glutamate and GABA in the supernatant 
were  measured  by  the  method  of  Lindroth  and  Mopper 
(1979), as modified by Sandberg and Corazzi (1983), apply-
ing  precolumn  o-phtaldialdehyde  derivatization.  The 
samples were injected on a Varian 500LC apparatus with a 
reversed-phase Supelcosil LC-18-DB column, a mixture of 
50 mM NaH2PO4 buffer (pH 5.25) and methanol as mobile 
phase, and a CMA/280 fluorescence detector. Gradient elu-
ation was used, with the amount of NaH2PO4 buffer chang-
ing from 75% to 25% over 20 minutes (Paulsen and Fonnum 
1988). The protein concentration in the pellet was measured 
by reaction with Folin-Ciocalteu reagent and analysis with 
a spectrophotometer at 750 nm, according to Lowry et al. 
(1951). GABA and glutamate concentrations in the mouse 
brains were calculated as µMol/mg protein.
Effect of 4MeI on [3H]GABA binding to cerebral GABA 
receptors
The effect of 4MeI on sodium independent binding of [3H]
GABA to synaptosomal membranes from mouse brain was 
investigated with a modified version of the method described 
by Hill et al. (1984) and Naalsund and Fonnum (1986). Brains 
from B6D2 mice were homogenized in 20 volumes of 0.32 M 
sucrose and centrifuged at 1000 xg for 10 minutes, and the 
pellet was washed once. The combined supernatants were 
then centrifuged at 20 000 xg for 20 minutes. The pellet from 216    Tore Sivertsen et al.
this  centrifugation  was  resuspended  to  the  same  volume 
with cold, distilled water to rupture membrane vesicles, and 
kept on ice for 1 hour. After centrifugation at 8000 xg for 20 
minutes the supernatant was gently decanted, and the upper 
layer of the pellet was rinsed off and added to the superna-
tant. These combined supernatants were recentrifuged at   
48 000 xg for 20 minutes, and the pellet stored frozen at −20°C 
prior to use. For the receptor binding assay, the membranes 
were thawed, resuspended in TrisHCl buffer (50 mM, pH 7.4), 
and incubated for 45 minutes at room temperature before 
centrifugation (8500 xg for 10 minutes). The membrane sus-
pension was further washed three times and incubated with 
the Tris-buffer for 15 minutes at room temperature between 
each centrifugation, to remove all endogenous ligand. The 
final pellet was resuspended to give a protein concentration 
of ca. 100 µg per assay.
Binding of [3H]GABA (final concentration 25 nM with a 
specific activity of 40 Ci/mmol) was assayed in the absence 
or presence of 1 mM unlabeled GABA, to determine the spe-
cific transmitter binding. Varying amounts of 4MeI (0, 5 µM, 
50 µM, 100 µM, 500 µM, 1 mM, 2 mM, 5 mM, and 50 mM final 
concentration) were added. All assay mixtures were diluted 
to a final volume of 500 µl with TrisHCl, before incubation 
for 60 minutes at 0°C. The membranes were collected on fil-
ters with a Skatron cell harvester, the filters were transferred 
to scintillation cups, dissolved in 10 ml Filter Count count-
ing liquid and counted in a Packard 2200CA liquid scintil-
lation analyzer. Three parallel assays without and two with 
unlabeled GABA were run for each 4MeI concentration. The 
complete series of assays was repeated four times, and the 
results calculated as GABA receptor binding in per cent of 
the mean binding without 4MeI.
Statistical analysis
In all comparisons, student’s t-test was used for statistical 
evaluation. Unless stated otherwise, the limit of statistical 
significance was set at p < 0.05.
Results
In the first set of experiments on cerebral GAD activity, 4MeI 
concentrations  from  5 µM  to  1 mM  did  not  reduce  GAD 
activity significantly, compared to control values. With 2 mM 
4MeI the GAD activity was reduced to 85.4% of controls (SD 
4.9%), with 5 mM to 77.9% (SD 7.1%), and with 10 mM 4MeI 
to 61.7% of controls (SD 10.4%). All these reductions were 
statistically significant (p < 0.05).
With the 4MeI concentration set at 5 mM, neither varia-
tion of pyridoxal phosphate concentrations in the assay mix-
ture from 0.9–9.3 µM nor variation of glutamate concentra-
tions from 575 µM to 9.2 mM did affect the influence of 4MeI 
on GAD activity significantly.
In the comparative experiment, all the substituted imi-
dazoles tested reduced the GAD activity significantly (p < 
0.01) in concentrations from 5–20 mM. In equal concentra-
tions, 2MeI had stronger effect on GAD activity than 4MeI 
(Figure 1). Twenty mM imidazole also reduced the GAD 
activity (p < 0.01), but with somewhat less effect (83.1% of 
control) than the substituted imidazoles.
After ip injection of 250 mg 4MeI/kg, all the mice tested 
developed sudden convulsive seizures, after a lag period 
varying from 3 minutes 50 seconds to 6 minutes 50 sec-
onds. They died in a few seconds after the onset of seizures. 
Average postmortem cerebral GABA concentrations in the 
poisoned mice were 22.1 µMol (SD 1.8 µMol) per mg pro-
tein, compared to 20.3 µMol (SD 1.0 µMol) per mg protein 
in the control mice. The average cerebral glutamate con-
centrations were 119.7 µMol (SD 9.8 µMol) per mg protein 
in the poisoned mice, and 114.6 µMol (SD 8.2 µMol) per mg 
protein in the controls. None of the differences between 
poisoned and control mice were statistically significant.
4MeI concentrations from 5 µM to 2 mM did not have a 
significant  effect  on  sodium  independent  binding  of  [3H]
GABA to synaptosomal membranes from mouse brain. With 
5 mM 4MeI present the [3H]GABA binding was significantly 
(p < 0.01) reduced; to 63.4% (SD 7.2%) of control values. With 
50 mM 4MeI the binding was reduced to 23.9% (SD 3.7%) of 
controls (p < 0.01).
Discussion
Since  the  original  report  of  Wiggins  (1956),  poisoning  of 
ruminants by ammoniated forage has been observed world-
wide. The poisoning is characterized by sudden episodes of 
agitated confusion, hyperexcitability, tremors, and convul-
sions (Morgan 2004). 4MeI was for many years generally 
accepted as the main etiologic agent in this poisoning syn-
drome (Osweiler 1996). Findings of very low concentrations 
of 4MeI in the feed and plasma of experimentally poisoned 
animals have complicated the picture (Sivertsen et al. 1993; 
Morgan 2004). Still, 4MeI is up to now the strongest and 
most  abundant  convulsive  agent  identified  in  poisonous 
ammoniated  forage  (Müller  et  al.  1998),  and  the  clinical 
signs of experimental 4MeI poisoning are indistinguishable 
from those of poisoning with ammoniated feed (Kristensen 
et al. 1991). Clonic seizures and hyperactivity have also been 
observed after oral exposure to 4MeI in long-term feeding 
































Figure 1.  Effect of different concentrations of 4-methylimidazole (4MeI), 
1-methylimidazole (1MeI), 2-methylimidazole (2MeI), 4-methylhydroxy-
imidazole (4MeOHI), and imidazole-4-acetic acid (4AcI) on mouse brain 
glutamate decarboxylase (GAD) activity in vitro: Per cent of control activ-
ity. Mean values, n ≥ 6. All means are significantly different from control 
values (p < 0.01).4-methylimidazole and GABA in mice    217
In lethal doses, the effect of 4MeI in mice is   characteristic 
and  dramatic.  Shortly  after  parenteral  administration  of 
250 mg/kg  4MeI  the  treated  mouse  may  show  moderate 
signs of CNS excitation: Raised tail, slight tremors, small 
squeaks and jumps, and repeated grooming of the muzzle 
with its fore paws. After a period of 3–7 minutes, the mouse 
goes  suddenly  into  violent  convulsions,  similar  to  those 
described by Gale (1992) as running-bouncing clonic sei-
zures. Within a short time, usually a few seconds, the sei-
zures end in a typical tonic extensor convulsive spasm (Gale 
1992) and death (Sivertsen and Müller 1999). This toxico-
logical picture requires that the number of animals used in 
in vivo studies should be kept as low as possible (Sivertsen 
and Müller 1999). Accordingly, the number of mice given 
toxic  4  MeI  doses  in  the  present  study  was  restricted  to 
five. From a mechanistic point of view, the clinical picture 
of acute 4MeI poisoning does in our opinion indicate that 
4MeI interferes with one or more of the major transmitter 
systems in the brain (Gale 1992; McNamara 2006).
In  the  present  study,  4MeI  was  found  to  have  a 
  dose-dependant inhibitory effect on GAD activity in vitro, 
statistically significant at concentrations of 2 mM or above. 
An average whole brain 4MeI concentration of 2.2 mMol/kg 
has been found in mice after lethal poisoning with 250 mg/kg 
(Sivertsen, Hassel, and Uhlig, unpublished), so the inhibitory 
concentrations in vitro are just within the range of relevant 
in vivo concentrations. In contrast, both mercaptopropio-
noic acid and mercaptobutyric acid show significant inhibi-
tion of GAD in vitro already at concentrations of 0.1–0.5 mM 
(Lamar  1970).  Neither  variation  in  glutamate  concentra-
tions nor of pyridoxal phosphate concentrations in the assay 
changed the strength of the inhibitory effect. This indicates 
that the inhibition of GAD was not competitive with regard 
to substrate or coenzyme in the enzymatic process. This is 
in contrast to the effect of mercaptopropionic acid, which is 
clearly competitive with respect to glutamate (Lamar 1970). 
Our  testing  of  other  substituted  imidazoles  showed  that 
they all had an inhibitory effect on GAD activity in the same 
range, with 2MeI giving the strongest inhibition of GAD. This 
is in contrast to experiments in vivo, where 1MeI and 2MeI 
show  much  weaker  tremorogenic  and  convulsive  activity 
than 4MeI (Nishie et al. 1969). Finally, lethal poisoning of 
mice with 4MeI did not change the cerebral levels of GABA, 
in strong contrast to the effect seen with mercaptopropionic 
acid (Karlsson et al. 1974). Taken together, these results do 
not confirm inhibition of cerebral GABA synthesis as a deci-
sive mechanism in 4MeI toxicity.
In  the  GABA  receptor  binding  experiments,  4MeI  was 
found to inhibit specific binding of [3H]GABA to cerebral 
GABA receptors, but the inhibition was statistically signifi-
cant only in concentrations at 5 mM or above, and 50 mM 
was  needed  to  inhibit  the  GABA  receptor  binding  with 
76%. As mentioned, these concentrations are higher than 
the whole brain concentrations of 4MeI after lethal poison-
ing. Therefore, also the inhibition of GABA receptor bind-
ing seems too weak to be a main mechanism in 4MeI CNS 
toxicity.
In conclusion, the results of this study do in our opinion 
indicate that neither 4MeI inhibition of GABA synthesis nor 
interference with specific GABA receptor binding in mouse 
brain provide a satisfactory explanation of the convulsive 
effect of 4MeI in mice.
As  mentioned  in  the  introduction, Nishie  et  al.  (1969) 
found that the convulsive effect of 4MeI could be counter-
acted by chlordiazepoxide and by sodium phenobarbital. 
Although benzodiazepines and barbiturates are known to act 
via the GABAA receptor, both groups have a clinically broad 
anticonvulsive  effect,  counteracting  seizures  induced  by 
different agents and pathological mechanisms (McNamara 
2006). The possibility that the convulsive effect of 4MeI is 
related to interference with cerebral GABA activity cannot 
yet be finally excluded, as some GABA receptor inhibitors 
like picrotoxin bind to other receptor sites than GABA itself 
(Olsen and Leeb-Lundberg 1981). Still, our results do indi-
cate that the effect of 4MeI on other receptor systems in the 
mammalian brain should be investigated.
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